

2019 Future of Multiple System Atrophy (MSA) R&D Pipeline Drugs and Companies- Analysis of Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

<https://marketpublishers.com/r/24997CF7B0BEN.html>

Date: February 2019

Pages: 50

Price: US\$ 2,199.00 (Single User License)

ID: 24997CF7B0BEN

Abstracts

The global demand for Multiple System Atrophy (MSA) treatment options is emerging rapidly driven by demand in major emerging and developed markets. An increasing number of companies are working on Multiple System Atrophy (MSA) pipeline. Companies quickly adapting to the new technologies both independently and through collaborations and advancing their pipeline candidates to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and limited financial support are holding some of the Multiple System Atrophy (MSA) pipeline companies from advancing their products into Phase 3 or Phase 4.

Multiple System Atrophy (MSA) Report Description-

The 2019 pipeline study on Multiple System Atrophy (MSA) pipeline is a comprehensive research on the drug candidates across different phases. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Multiple System Atrophy (MSA) pipeline compounds.

The Multiple System Atrophy (MSA) pipeline guide presents information on all active drugs currently being developed for Multiple System Atrophy (MSA). The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.

Details of current status, R&D progress and latest developments for every Multiple System Atrophy (MSA) pipeline candidate are analyzed.

Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Multiple System Atrophy (MSA) drug candidates.

Drug development companies, collaborators, originating companies, license providers and universities participating in the Multiple System Atrophy (MSA) product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.

The report assists in identifying potential upcoming companies and drugs in Multiple System Atrophy (MSA) pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

VPA Research has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.

Scope of Multiple System Atrophy (MSA) pipeline report includes-

An overview of Multiple System Atrophy (MSA) disease including symptoms, causes, diagnosis and available treatment options is provided.

Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc

Phase wise count of Multiple System Atrophy (MSA) pipeline

Company wise list of Multiple System Atrophy (MSA) pipeline

Mechanism of Action wise Multiple System Atrophy (MSA) pipeline

For each pipeline candidate, the following details are provided

Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator, Synonym, Orphan Drug Status, New Molecular Entity, Area)

Current status of development

Drug overview

Mechanism of Action

Pre-clinical and Clinical Trials/Results

Company Overview and Recent Developments

REASONS TO BUY

The report is designed to help industry executives promote the success and continued growth of their organizations

Get clear understanding of the entire Multiple System Atrophy (MSA) pipeline, with details on active projects

Stay ahead of the competition through comprehensive knowledge of Multiple System Atrophy (MSA) pipeline progress

Get in detail information of each product with updated information on each project along with key milestones

Gain clear insights into companies participating in Multiple System Atrophy (MSA) pipeline along with progress of each of the company's products and information on associations/collaborations/licensing data

Get trial information for each pipeline product under development

Understand the pipeline structure in terms of mechanism of Action, phase and company

The report will be delivered in 2 working days.

Contents

1. TABLE OF CONTENTS

- 1.1 List of Tables
- 1.2 List of Figures

2. GLOBAL MULTIPLE SYSTEM ATROPHY (MSA) PIPELINE OVERVIEW

- 2.1 Key Findings, 2019
- 2.2 Disease Overview
- 2.3 Research Methodology

3. EXECUTIVE SUMMARY

- 3.1 Multiple System Atrophy (MSA) Drugs under active development, H1- 2019
- 3.2 Pipeline Drugs in Early Stage of Development
 - 3.2.1 Pre-clinical
 - 3.2.2 Discovery
 - 3.2.3 Phase
 - 3.2.4Phase
- 3.3 Pipeline Drugs in Advanced Stage of Development
 - 3.3.1 Phase
 - 3.3.2 Pre-registration
- 3.4 Companies involved in Multiple System Atrophy (MSA) pipeline, H1- 2019
- 3.5 Mechanism of Action wise Multiple System Atrophy (MSA) Pipeline Candidates

4 AFFIRIS AG MULTIPLE SYSTEM ATROPHY (MSA)/SHY-DRAGER SYNDROME PIPELINE DETAILS

- 4.1 AFFiRiS AG Business Profile
- 4.2 AFFiRiS AG Multiple System Atrophy (MSA)/Shy-Drager Syndrome Drug Details
- 4.3 Drug Snapshot
 - 4.3.1 Originator
 - 4.3.2 Collaborator/Co-Developer
 - 4.3.3 Route of Administration
 - 4.3.4 Orphan Drug/Fast Track/Special Designation
 - 4.3.5 Geography
 - 4.3.6 Type of Molecular Entity

- 4.3.7 Current Status
- 4.4 Drug Overview
- 4.5 Drug Mechanism of Action
- 4.6 Clinical/Pre-clinical Trial Details
- 4.7 Latest Drug Developments

5 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY MULTIPLE SYSTEM ATROPHY (MSA)/SHY-DRAGER SYNDROME PIPELINE DETAILS

- 5.1 Biohaven Pharmaceutical Holding Company Business Profile
- 5.2 Biohaven Pharmaceutical Holding Company Multiple System Atrophy (MSA)/Shy-Drager Syndrome Drug Details
- 5.3 Drug Snapshot
 - 5.3.1 Originator
 - 5.3.2 Collaborator/Co-Developer
 - 5.3.3 Route of Administration
 - 5.3.4 Orphan Drug/Fast Track/Special Designation
 - 5.3.5 Geography
 - 5.3.6 Type of Molecular Entity
 - 5.3.7 Current Status
- 5.4 Drug Overview
- 5.5 Drug Mechanism of Action
- 5.6 Clinical/Pre-clinical Trial Details
- 5.7 Latest Drug Developments

6 CORESTEM INC MULTIPLE SYSTEM ATROPHY (MSA)/SHY-DRAGER SYNDROME PIPELINE DETAILS

- 6.1 Corestem Inc Business Profile
- 6.2 Corestem Inc Multiple System Atrophy (MSA)/Shy-Drager Syndrome Drug Details
- 6.3 Drug Snapshot
 - 6.3.1 Originator
 - 6.3.2 Collaborator/Co-Developer
 - 6.3.3 Route of Administration
 - 6.3.4 Orphan Drug/Fast Track/Special Designation
 - 6.3.5 Geography
 - 6.3.6 Type of Molecular Entity
 - 6.3.7 Current Status
- 6.4 Drug Overview

- 6.5 Drug Mechanism of Action
- 6.6 Clinical/Pre-clinical Trial Details
- 6.7 Latest Drug Developments

7 DENALI THERAPEUTICS INC MULTIPLE SYSTEM ATROPHY (MSA)/SHY-DRAGER SYNDROME PIPELINE DETAILS

- 7.1 Denali Therapeutics Inc Business Profile
- 7.2 Denali Therapeutics Inc Multiple System Atrophy (MSA)/Shy-Drager Syndrome Drug Details
- 7.3 Drug Snapshot
 - 7.3.1 Originator
 - 7.3.2 Collaborator/Co-Developer
 - 7.3.3 Route of Administration
 - 7.3.4 Orphan Drug/Fast Track/Special Designation
 - 7.3.5 Geography
 - 7.3.6 Type of Molecular Entity
 - 7.3.7 Current Status
- 7.4 Drug Overview
- 7.5 Drug Mechanism of Action
- 7.6 Clinical/Pre-clinical Trial Details
- 7.7 Latest Drug Developments

8 ENTERIN INC MULTIPLE SYSTEM ATROPHY (MSA)/SHY-DRAGER SYNDROME PIPELINE DETAILS

- 8.1 Enterin Inc Business Profile
- 8.2 Enterin Inc Multiple System Atrophy (MSA)/Shy-Drager Syndrome Drug Details
- 8.3 Drug Snapshot
 - 8.3.1 Originator
 - 8.3.2 Collaborator/Co-Developer
 - 8.3.3 Route of Administration
 - 8.3.4 Orphan Drug/Fast Track/Special Designation
 - 8.3.5 Geography
 - 8.3.6 Type of Molecular Entity
 - 8.3.7 Current Status
- 8.4 Drug Overview
- 8.5 Drug Mechanism of Action
- 8.6 Clinical/Pre-clinical Trial Details

8.7 Latest Drug Developments

9 ICB INTERNATIONAL INC MULTIPLE SYSTEM ATROPHY (MSA)/SHY-DRAGER SYNDROME PIPELINE DETAILS

9.1 ICB International Inc Business Profile

9.2 ICB International Inc Multiple System Atrophy (MSA)/Shy-Drager Syndrome Drug Details

9.3 Drug Snapshot

9.3.1 Originator

9.3.2 Collaborator/Co-Developer

9.3.3 Route of Administration

9.3.4 Orphan Drug/Fast Track/Special Designation

9.3.5 Geography

9.3.6 Type of Molecular Entity

9.3.7 Current Status

9.4 Drug Overview

9.5 Drug Mechanism of Action

9.6 Clinical/Pre-clinical Trial Details

9.7 Latest Drug Developments

10 INHIBIKASE THERAPEUTICS MULTIPLE SYSTEM ATROPHY (MSA)/SHY-DRAGER SYNDROME PIPELINE DETAILS

10.1 Inhibikase Therapeutics Business Profile

10.2 Inhibikase Therapeutics Multiple System Atrophy (MSA)/Shy-Drager Syndrome Drug Details

10.3 Drug Snapshot

10.3.1 Originator

10.3.2 Collaborator/Co-Developer

10.3.3 Route of Administration

10.3.4 Orphan Drug/Fast Track/Special Designation

10.3.5 Geography

10.3.6 Type of Molecular Entity

10.3.7 Current Status

10.4 Drug Overview

10.5 Drug Mechanism of Action

10.6 Clinical/Pre-clinical Trial Details

10.7 Latest Drug Developments

11 MITODYS THERAPEUTICS LTD MULTIPLE SYSTEM ATROPHY (MSA)/SHY-DRAGER SYNDROME PIPELINE DETAILS

- 11.1 MitoDys Therapeutics Ltd Business Profile
- 11.2 MitoDys Therapeutics Ltd Multiple System Atrophy (MSA)/Shy-Drager Syndrome Drug Details
- 11.3 Drug Snapshot
 - 11.3.1 Originator
 - 11.3.2 Collaborator/Co-Developer
 - 11.3.3 Route of Administration
 - 11.3.4 Orphan Drug/Fast Track/Special Designation
 - 11.3.5 Geography
 - 11.3.6 Type of Molecular Entity
 - 11.3.7 Current Status
- 11.4 Drug Overview
- 11.5 Drug Mechanism of Action
- 11.6 Clinical/Pre-clinical Trial Details
- 11.7 Latest Drug Developments

12 MODAG GMBH MULTIPLE SYSTEM ATROPHY (MSA)/SHY-DRAGER SYNDROME PIPELINE DETAILS

- 12.1 Modag GmbH Business Profile
- 12.2 Modag GmbH Multiple System Atrophy (MSA)/Shy-Drager Syndrome Drug Details
- 12.3 Drug Snapshot
 - 12.3.1 Originator
 - 12.3.2 Collaborator/Co-Developer
 - 12.3.3 Route of Administration
 - 12.3.4 Orphan Drug/Fast Track/Special Designation
 - 12.3.5 Geography
 - 12.3.6 Type of Molecular Entity
 - 12.3.7 Current Status
- 12.4 Drug Overview
- 12.5 Drug Mechanism of Action
- 12.6 Clinical/Pre-clinical Trial Details
- 12.7 Latest Drug Developments

13 NEUROPORE THERAPIES INC MULTIPLE SYSTEM ATROPHY (MSA)/SHY-

DRAGER SYNDROME PIPELINE DETAILS

- 13.1 Neuropore Therapies Inc Business Profile
- 13.2 Neuropore Therapies Inc Multiple System Atrophy (MSA)/Shy-Drager Syndrome Drug Details
- 13.3 Drug Snapshot
 - 13.3.1 Originator
 - 13.3.2 Collaborator/Co-Developer
 - 13.3.3 Route of Administration
 - 13.3.4 Orphan Drug/Fast Track/Special Designation
 - 13.3.5 Geography
 - 13.3.6 Type of Molecular Entity
 - 13.3.7 Current Status
- 13.4 Drug Overview
- 13.5 Drug Mechanism of Action
- 13.6 Clinical/Pre-clinical Trial Details
- 13.7 Latest Drug Developments

14 PRANA BIOTECHNOLOGY LTD MULTIPLE SYSTEM ATROPHY (MSA)/SHY-DRAGER SYNDROME PIPELINE DETAILS

- 14.1 Prana Biotechnology Ltd Business Profile
- 14.2 Prana Biotechnology Ltd Multiple System Atrophy (MSA)/Shy-Drager Syndrome Drug Details
- 14.3 Drug Snapshot
 - 14.3.1 Originator
 - 14.3.2 Collaborator/Co-Developer
 - 14.3.3 Route of Administration
 - 14.3.4 Orphan Drug/Fast Track/Special Designation
 - 14.3.5 Geography
 - 14.3.6 Type of Molecular Entity
 - 14.3.7 Current Status
- 14.4 Drug Overview
- 14.5 Drug Mechanism of Action
- 14.6 Clinical/Pre-clinical Trial Details
- 14.7 Latest Drug Developments

15 UNITED NEUROSCIENCE INC MULTIPLE SYSTEM ATROPHY (MSA)/SHY-DRAGER SYNDROME PIPELINE DETAILS

- 15.1 United Neuroscience Inc Business Profile
- 15.2 United Neuroscience Inc Multiple System Atrophy (MSA)/Shy-Drager Syndrome Drug Details
- 15.3 Drug Snapshot
 - 15.3.1 Originator
 - 15.3.2 Collaborator/Co-Developer
 - 15.3.3 Route of Administration
 - 15.3.4 Orphan Drug/Fast Track/Special Designation
 - 15.3.5 Geography
 - 15.3.6 Type of Molecular Entity
 - 15.3.7 Current Status
- 15.4 Drug Overview
- 15.5 Drug Mechanism of Action
- 15.6 Clinical/Pre-clinical Trial Details
- 15.7 Latest Drug Developments

16. LATEST MULTIPLE SYSTEM ATROPHY (MSA) DRUG PIPELINE DEVELOPMENTS, 2019

17. APPENDIX

- 17.1 About Us
- 17.2 Sources and Methodology
- 17.3 Contact Information

I would like to order

Product name: 2019 Future of Multiple System Atrophy (MSA) R&D Pipeline Drugs and Companies- Analysis of Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

Product link: <https://marketpublishers.com/r/24997CF7B0BEN.html>

Price: US\$ 2,199.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/24997CF7B0BEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970